February 20, 2015
Impax Laboratories Inc. has reached an $8 million settlement with a class of shareholders who allege that the company downplayed U.S. Food and Drug Administration concerns over quality control at a California plant, it was announced Friday.
July 29, 2014
Impax Laboratories Inc. on Tuesday disclosed the U.S. Food and Drug Administration's objections to extensive quality lapses at a Taiwan manufacturing plant for its proposed Parkinson's disease medication Rytary, adding to previous production woes that have fueled investor lawsuits over lengthy delays of the drug.
April 18, 2014
A California federal judge on Friday refused to toss a securities fraud class action against Impax Laboratories Inc. that alleges the pharmaceutical company hid serious quality-control deficiencies while exaggerating its progress toward fixing them.